Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Hsien S, Dayton JD, Chen D, Stock A, Bacha E, Cushing MM, et al. Hemostatic efficacy of pathogen-reduced platelets in children undergoing cardiopulmonary bypass. Transfusion. 2022;62(2):298-305.

Stover EH, Oh C, Keskula P, Choudhury AD, Tseng Y-, Adalsteinsson VA, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. Prostate. 2022;82(5):584-597.

De La Vega LL, Comeau H, Sallan S, Al-Ibraheemi A, Gupta H, Li YY, et al. Rare FGFR Oncogenic Alterations in Sequenced Pediatric Solid and Brain Tumors Suggest FGFR Is a Relevant Molecular Target in Childhood Cancer. JCO Precis Oncol. 2022;6:e2200390.

Kim D, Burkhardt R, Alperstein SA, Gokozan HN, Goyal A, Heymann JJ, et al. Evaluating the role of Z-stack to improve the morphologic evaluation of urine cytology whole slide images for high-grade urothelial carcinoma: Results and review of a pilot study. Cancer Cytopathol. 2022;130(8):630-639.

Liechty B, Xu Z, Zhang Z, Slocum C, Bahadir CD, Sabuncu MR, et al. Machine learning can aid in prediction of IDH mutation from H&E-stained histology slides in infiltrating gliomas. Sci Rep. 2022;12(1):22623.

Bickett TE, Knitz MW, Piper M, Oweida AJ, Gadwa J, Darragh LB, et al. Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC. Mol Ther. 2022;30(3):1149-1162.

Liao D, Geyer JT, Kacker A. Cervical Lymphadenopathy in an Elderly Man. JAMA Otolaryngol Head Neck Surg. 2022;148(7):686-687.

Saliba M, Alzumaili BA, Katabi N, Dogan S, Tuttle RM, Zoltan A, et al. Clinicopathologic and Prognostic Features of Pediatric Follicular Cell-derived Thyroid Carcinomas: A Retrospective Study of 222 Patients. Am J Surg Pathol. 2022;46(12):1659-1669.

Kudalkar EM, Pang C, Haag MM, Pollyea DA, Kamdar M, Xu G, et al. 21q22 amplification detection in three patients with acute myeloid leukemia: cytogenomic profiling and literature review. Mol Cytogenet. 2022;15(1):30.

Xiang G, Wang S, Chen L, Song M, Song X, Wang H, et al. UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer. Cell Death Dis. 2022;13(5):451.